VolitionRX(VNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VNRX VolitionRX

Not Yet Opened 01-20 16:00:00 EST

0.3179

+0.0247

+8.42%

盘后0.3232

+0.0053+1.67%

19:52 EST

High0.3500	Low0.2800	Vol7.99M
Open0.3300	D1 Closing0.2932	Amplitude23.87%
Mkt Cap39.04M	Tradable Cap28.34M	Total Shares122.80M
T/O2.65M	T/O Rate8.96%	Tradable Shares89.14M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VNRX","market":"US","secType":"STK","nameCN":"VolitionRX","latestPrice":0.3179,"timestamp":1768942800000,"preClose":0.2932,"halted":0,"volume":7989849,"hourTrading":{"tag":"盘后","latestPrice":0.3232,"preClose":0.3179,"latestTime":"19:52 EST","volume":34127,"amount":10938.491823,"timestamp":1768956748844,"change":0.0053,"changeRate":0.016672,"amplitude":0.072035},"delay":0,"changeRate":0.08424283765347886,"floatShares":89140332,"shares":122801572,"eps":-0.22881,"marketStatus":"Not Yet Opened","change":0.0247,"latestTime":"01-20 16:00:00 EST","open":0.33,"high":0.35,"low":0.28,"amount":2645701.5503381398,"amplitude":0.238745,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.22881,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768986000000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1423198800000,"exchange":"AMEX","adjPreClose":0.2932,"preHourTrading":{"tag":"盘前","latestPrice":0.339,"preClose":0.2932,"latestTime":"09:29 EST","volume":679512,"amount":222637.82587439998,"timestamp":1768919394936,"change":0.0458,"changeRate":0.156207,"amplitude":0.141201},"postHourTrading":{"tag":"盘后","latestPrice":0.3232,"preClose":0.3179,"latestTime":"19:52 EST","volume":34127,"amount":10938.491823,"timestamp":1768956748844,"change":0.0053,"changeRate":0.016672,"amplitude":0.072035},"volumeRatio":8.67751,"impliedVol":0.1508,"impliedVolPercentile":0.3506},"requestUrl":"/m/hq/s/VNRX","defaultTab":"news","newsList":[{"id":"2604115480","title":"VolitionRX Expands Nu.Q Vet Cancer Test Access With New Laboratory Providers","url":"https://stock-news.laohu8.com/highlight/detail?id=2604115480","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604115480?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:25","pubTimestamp":1768915514,"startTime":"0","endTime":"0","summary":"VolitionRx Limited announced the appointment of two new centralized laboratory providers for its Nu.Q Vet Cancer test in the United States and Asia. Midwest Veterinary Laboratory will offer the Nu.Q Vet Cancer test to customers across all 50 U.S. states starting February 2026. Bioguard, an animal health diagnostics company, will provide the test through its Animal Health Diagnostic Center, which is certified in Taiwan and China.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via PR Newswire  on January 20, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDLn46fg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","VNRX"],"gpt_icon":0},{"id":"2603991979","title":"VolitionRX Ltd. Showcases Nu.Q Vet Cancer Test at VMX Veterinary Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2603991979","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603991979?lang=en_us&edition=fundamental","pubTime":"2026-01-16 21:45","pubTimestamp":1768571113,"startTime":"0","endTime":"0","summary":"VolitionRx Ltd. will sponsor an industry symposium at the Veterinary Meeting and Expo  in Orlando, Florida. Dr. Sue Ettinger, also known as \"Dr Sue Cancer Vet,\" will present \"Utilizing the Nu.Q Vet Cancer Test in Practice\" on Monday, January 19 at 2:45pm EST. The Volition Veterinary Diagnostics Development team will also be available at booth 2243 during the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via PR Newswire  on January 16, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDL3qj77w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNRX","BK4198"],"gpt_icon":0},{"id":"2602373847","title":"VolitionRX Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2602373847","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602373847?lang=en_us&edition=fundamental","pubTime":"2026-01-09 20:15","pubTimestamp":1767960900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VNRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 09, 2026 07:15 ET (12:15 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNRX"],"gpt_icon":0},{"id":"2601292360","title":"BRIEF-Volitionrx Ltd Enters Amended Securities Purchase Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2601292360","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601292360?lang=en_us&edition=fundamental","pubTime":"2026-01-08 22:22","pubTimestamp":1767882155,"startTime":"0","endTime":"0","summary":"BRIEF-Volitionrx Ltd Enters Amended Securities Purchase AgreementJan 8 (Reuters) - VolitionRX Ltd VNRX.A:VOLITIONRX LTD - ENTERS AMENDED SECURITIES PURCHASE AGREEMENTVOLITIONRX LTD - TO RECEIVE $2,000","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y911A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","VNRX"],"gpt_icon":0},{"id":"2601606433","title":"VolitionRX Ltd - Enters Amended Securities Purchase Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2601606433","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601606433?lang=en_us&edition=fundamental","pubTime":"2026-01-08 22:15","pubTimestamp":1767881746,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y911A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VNRX","BK4198"],"gpt_icon":0},{"id":"2601606173","title":"VolitionRX Ltd - to Receive $2,000,000 From Investor","url":"https://stock-news.laohu8.com/highlight/detail?id=2601606173","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601606173?lang=en_us&edition=fundamental","pubTime":"2026-01-08 22:15","pubTimestamp":1767881746,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y911A:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4198","VNRX"],"gpt_icon":0},{"id":"2601668360","title":"Press Release: VolitionRx Secures $2.0 Million in Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=2601668360","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601668360?lang=en_us&edition=fundamental","pubTime":"2026-01-08 22:15","pubTimestamp":1767881700,"startTime":"0","endTime":"0","summary":"HENDERSON, Nev., Jan. 8, 2026 /PRNewswire/ -- VolitionRx Limited  , a multi-national epigenetics company, announced today that it has entered into an amended and restated securities purchase agreement  with Lind Global Asset Management XII LLC , an investment fund managed by The Lind Partners, a New York-based institutional fund manager. Under the Amended Agreement, the Company will receive aggregate gross proceeds of $2,000,000 from the Investor in exchange for the issuance to the Investor of a senior secured convertible promissory note in the principal amount of $2,400,000 , and a five-year common stock purchase warrant to purchase up to 7,000,350 shares of the Company's common stock at an exercise price of $0.5714 per share , subject to the satisfaction of certain closing conditions. As additional consideration to Investor, we have agreed to pay a commitment fee in the amount of $70,000, which shall be paid by deduction from the funding to be received.This press release shall not co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","BK4022","BK4099","BK4555","BK4585","VNRX","BK4588","BK4232","TM","03160","BK4604","R"],"gpt_icon":0},{"id":"2601935367","title":"VolitionRX Ltd. unveils corporate deck highlighting cancer and sepsis diagnostics, licensing strategy, and global commercialization plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2601935367","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601935367?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:55","pubTimestamp":1767880516,"startTime":"0","endTime":"0","summary":"VolitionRX Ltd. unveils corporate deck highlighting cancer and sepsis diagnostics, licensing strategy, and global commercialization plans. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief on January 08, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL62BtzR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","VNRX"],"gpt_icon":0},{"id":"2601367877","title":"VolitionRx Unveils Breakthrough Liquid Biopsy Test for Feline Cancer Detection","url":"https://stock-news.laohu8.com/highlight/detail?id=2601367877","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601367877?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:45","pubTimestamp":1767879922,"startTime":"0","endTime":"0","summary":"VolitionRx Limited has announced results from a clinical study evaluating its Nu.Q Vet Feline assay for the detection of lymphoma in cats. According to the company, the assay demonstrated over 80% detection of feline lymphomas at 100% specificity, indicating no false positives. These results pave the way for what is expected to be the world’s first blood-based liquid biopsy test for feline cancer. The study results have already been announced, and the publication of the study in a peer-reviewed journal is expected to follow. VolitionRx plans to complete product development and make the Nu.Q Vet Feline Test available through existing distribution networks.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the orig","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL75XhGp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNRX","BK4198"],"gpt_icon":0},{"id":"2601824367","title":"VolitionRX Announces Breakthrough Clinical Data for Nu.q® Vet Cancer Test in Cats","url":"https://stock-news.laohu8.com/highlight/detail?id=2601824367","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601824367?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:45","pubTimestamp":1767879900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA25Y4K4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4198","VNRX"],"gpt_icon":0},{"id":"2592590580","title":"VolitionRX Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2592590580","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592590580?lang=en_us&edition=fundamental","pubTime":"2025-12-18 20:33","pubTimestamp":1766061180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VNRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 18, 2025 07:33 ET (12:33 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNRX"],"gpt_icon":0},{"id":"2592091801","title":"VolitionRX Signs Licencing Agreements With Werfen and Hologic","url":"https://stock-news.laohu8.com/highlight/detail?id=2592091801","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592091801?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:45","pubTimestamp":1765979120,"startTime":"0","endTime":"0","summary":"VolitionRx Limited announced the signing of two agreements in 2025 as part of its human licensing strategy. The first agreement is with Werfen for Antiphospholipid Syndrome , and the second is a Co-Marketing and Services Agreement with Hologic. Additionally, in March, VolitionRx signed an agreement with a leading pharmaceutical company to use its Nu.Q Discover biomarkers in a longitudinal Phase 1/2b clinical study.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief on December 17, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL9kJMD1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2125909593.SGD","BK4198","LU1951200564.SGD","LU2433249047.HKD","BK4588","HOLX","BK4585","LU1923622614.USD","LU0823416689.USD","LU1951198990.SGD","LU0314104364.USD","BK4082","VNRX","LU1923623000.USD","LU2125909247.SGD"],"gpt_icon":0},{"id":"2590540544","title":"VolitionRX Ltd - on Dec 5 Volition Veterinary Terminated CEO DR. Butera Effective January 31, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2590540544","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590540544?lang=en_us&edition=fundamental","pubTime":"2025-12-12 06:01","pubTimestamp":1765490518,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nFWN3XH16K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4198","VNRX"],"gpt_icon":0},{"id":"2590544505","title":"Volition Veterinary Eliminates CEO Role Amid Cost Realignment","url":"https://stock-news.laohu8.com/highlight/detail?id=2590544505","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590544505?lang=en_us&edition=fundamental","pubTime":"2025-12-12 06:01","pubTimestamp":1765490464,"startTime":"0","endTime":"0","summary":"Volition Veterinary, a VolitionRX Subsidiary, to Eliminate CEO Position in Cost-Realignment Move. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 11, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL8rHVGW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNRX","BK4198"],"gpt_icon":0},{"id":"2590511820","title":"VolitionRX Unveils Breakthrough Liquid Biopsy Method Achieving 100% Cancer Detection in Early Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2590511820","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590511820?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:01","pubTimestamp":1765461669,"startTime":"0","endTime":"0","summary":"VolitionRx Ltd. has announced the preprint availability of a new manuscript detailing a novel method, Capture-Seq, and new biomarkers for cancer detection. The study involved a training cohort of 70 individuals, including 49 patients with breast, prostate, lung, or colorectal cancer. Results showed that the analysis of ultrashort transcription factor-bound DNA in plasma detected all cancer patients  and produced no false positives , including those with early-stage disease. These initial findings have not yet been validated in larger independent studies. The company also reported achieving a 180-fold enrichment of target DNA fragments and indicated that the technology may expand its Nu.Q portfolio. The results have been made available in a preprint and have not yet been presented in a peer-reviewed forum.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL5D90Kg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","VNRX"],"gpt_icon":0},{"id":"2589356690","title":"VolitionRx Unveils Promising Nu.Q Cancer Blood Test Data for Lung Cancer Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2589356690","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589356690?lang=en_us&edition=fundamental","pubTime":"2025-12-08 22:00","pubTimestamp":1765202459,"startTime":"0","endTime":"0","summary":"VolitionRx Ltd., a multi-national epigenetics company, announced the presentation of two abstracts at the North America Conference on Lung Cancer  in Chicago. The studies highlighted the use of Volition's Nu.Q Cancer assays in the management of lung cancer patients. Results from these studies were presented at the conference. One study demonstrated that Nu.Q Cancer assays, particularly the measurement of circulating H3K27Me3-nucleosomes, can support clinicians in treatment selection and patient monitoring, potentially improving prognostic accuracy and informing personalized care strategies. Another study found that pre-operative measurement of H3K27Me3-nucleosomes through a blood test may help stratify risk in Non Small Cell Lung Cancer patients, particularly in identifying those who may benefit from closer follow-up or additional treatment. The research indicates that Nu.Q-H3K27Me3 levels correlate with cancer stage and could serve as an independent prognostic biomarker for overall su","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL1r5YFR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","VNRX"],"gpt_icon":0},{"id":"2589566853","title":"Volition Announces Two Abstracts Were Presented at the North America Conference on Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2589566853","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589566853?lang=en_us&edition=fundamental","pubTime":"2025-12-08 22:00","pubTimestamp":1765202406,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nTUA899SPZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VNRX","BK4198"],"gpt_icon":0},{"id":"2588470887","title":"VolitionRx Nu.Q NETs Assay Selected for French Sepsis Detection Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2588470887","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588470887?lang=en_us&edition=fundamental","pubTime":"2025-12-04 22:02","pubTimestamp":1764856921,"startTime":"0","endTime":"0","summary":"VolitionRx Limited has announced the inclusion of its Nu.Q NETs H3.1 assay in the DETECSEPS real-world evaluation study for early detection of sepsis in France. The DETECSEPS Consortium, supported by approximately 6.3 million in French government funding as part of the France 2030 plan, will utilize the Nu.Q H3.1 assay as the sole biomarker in the study. The assay is designed to be used alongside the NEWS2 diagnostic test and can be processed using the Immunodiagnostic Systems  i10 automated analyzer. Results from the study have not yet been presented and are expected in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via PR Newswire  on December","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL1TS8wN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","VNRX","BK4121","RVTY","BK4198","BK4588"],"gpt_icon":0},{"id":"2588029512","title":"VolitionRX Shares Fall After Maxim Downgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2588029512","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588029512?lang=en_us&edition=fundamental","pubTime":"2025-12-04 03:58","pubTimestamp":1764791898,"startTime":"0","endTime":"0","summary":"VolitionRX (VNRX) shares were down nearly 7% in recent Wednesday trading after Maxim downgraded the company's stock to hold from buy.Trading volume stood at about 782,000 shares against a daily average of around 1.2 million.Price: 0.28, Change: -0.02, Percent Change: -6.86","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VNRX"],"gpt_icon":0},{"id":"2588026499","title":"VolitionRX Cut to Hold From Buy by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2588026499","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588026499?lang=en_us&edition=fundamental","pubTime":"2025-12-04 03:19","pubTimestamp":1764789540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VNRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 03, 2025 14:19 ET (19:19 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","VNRX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.volition.com","stockEarnings":[{"period":"1week","weight":0.0092},{"period":"1month","weight":0.2418},{"period":"3month","weight":-0.2467},{"period":"6month","weight":-0.5647},{"period":"1year","weight":-0.4939},{"period":"ytd","weight":0.2437}],"compareEarnings":[{"period":"1week","weight":-0.0233},{"period":"1month","weight":-0.0044},{"period":"3month","weight":0.0146},{"period":"6month","weight":0.068},{"period":"1year","weight":0.1339},{"period":"ytd","weight":-0.0064}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 worldwide. It offers Nu.Q Vet cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer that detect cancer; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company is based in Henderson, Nevada.","yearOnYearQuotes":[{"month":1,"riseRate":0.727273,"avgChangeRate":0.125358},{"month":2,"riseRate":0.3,"avgChangeRate":-0.068577},{"month":3,"riseRate":0.181818,"avgChangeRate":-0.06613},{"month":4,"riseRate":0.272727,"avgChangeRate":-0.026908},{"month":5,"riseRate":0.454545,"avgChangeRate":-0.041011},{"month":6,"riseRate":0.454545,"avgChangeRate":0.012813},{"month":7,"riseRate":0.272727,"avgChangeRate":-0.017569},{"month":8,"riseRate":0.545455,"avgChangeRate":0.012627},{"month":9,"riseRate":0.363636,"avgChangeRate":0.038825},{"month":10,"riseRate":0.363636,"avgChangeRate":-0.008979},{"month":11,"riseRate":0.363636,"avgChangeRate":0.018412},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.037586}],"exchange":"AMEX","name":"VolitionRX","nameEN":"VolitionRX"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"VolitionRX(VNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest VolitionRX(VNRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"VolitionRX,VNRX,VolitionRX股票,VolitionRX股票老虎,VolitionRX股票老虎国际,VolitionRX行情,VolitionRX股票行情,VolitionRX股价,VolitionRX股市,VolitionRX股票价格,VolitionRX股票交易,VolitionRX股票购买,VolitionRX股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"VolitionRX(VNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest VolitionRX(VNRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}